An interventional study of haplo-cord HSCT and Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX) in MDS (Myelodysplastic Syndrome) and AML (Acute Myeloid Leukemia), sponsored by Fujian Medical University Union Hospital. Recruiting at 4 sites in China. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Fujian Medical University Union Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 46th largest by planned enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2025, is one of 13 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 186th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 2–75
Roswell Park Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 14 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 13 · Phase 4 3
First in 1996; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 47 across the 188 interventional studies. Of the 129 that completed or were terminated, 75 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 191 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
14 of the studies testing fludarabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
| NCT02143830Children's Hospital Medical Center, CincinnatiHSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | 2026-12 |
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT04375631Fred Hutchinson Cancer CenterCLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | 2027-02-28 |
| NCT04872595Memorial Sloan Kettering Cancer CenterA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice.
Specific research objectives I. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates.
II. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis.
III. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making.
Novelty of the Study I. Innovation in Hematopoietic Stem Cell Infusion Schedule The present study employs a sequential infusion strategy: haploidentical stem cells are infused on Day 0, and umbilical cord blood cells are infused on Day +6 after transplantation.In contrast to the conventional approach used at most domestic and international centers (including the uzhou Protocol), in which both stem cell sources are infused simultaneously on Day 0, the current protocol delays cord blood infusion. This design confers potential advantages for immune reconstitution and long-term cord blood engraftment.
II. Unique Myeloablative Conditioning Regimen
The conditioning regimen used in this study is as follows:
Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days.
(For patients in complete remission (CR) with negative MRD before transplantation, Fludarabine and Cytarabine are administered for 3 days instead of 5 days.) Distinct from regimens at other centers, our team administers cyclophosphamide within the critical window after haploidentical stem cell infusion but before cord blood infusion, establishing a novel sequential conditioning model. This approach balances myeloablative intensity and immunomodulation, creating a favorable environment for subsequent long-term cord blood engraftment.
III. Engraftment Outcomes and Clinical Value Preliminary clinical experience demonstrates that haplo-cord sequential transplantation following the FA5Cy2Bu3 conditioning regimen combined with low-dose ATG/PTCY can achieve long-term cord blood engraftment in approximately 50% of patients.
By comparison, other domestic protocols (e.g., the Suzhou Protocol) rarely result in sustained cord blood engraftment.
Achievement of long-term cord blood engraftment is clinically meaningful for reducing relapse rates, lowering the incidence and severity of graft-versus-host disease (GVHD), and improving patient prognosis. These outcomes represent a key advantage of the present protocol.
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) are common and rapidly progressive malignant hematologic disorders associated with poor prognosis without effective intervention. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only first-line therapeutic strategy with curative potential for long-term remission or even definitive cure. However, the efficacy of conventional transplantation approaches is limited by multiple factors, particularly the management of graft-versus-host disease (GVHD) and disease recurrence. Balancing the graft-versus-leukemia (GVL) effect against residual leukemia while effectively mitigating GVHD represents an unresolved challenge in current transplantation strategies.
Although an HLA-matched donor is the optimal choice, access to such donors is restricted by time constraints and availability. In recent years, the widespread use of haploidentical donors has dramatically improved transplant accessibility, enabling nearly all patients to identify a suitable donor. China has emerged as a global leader in the development and application of haploidentical transplantation. Nevertheless, the established Beijing Protocol and the Baltimore post-transplantation cyclophosphamide (PTCY) regimen each have distinct limitations: the former is associated with high engraftment rates and low relapse incidence but a relatively high rate of chronic GVHD (approximately 20%), whereas the latter reduces GVHD risk but carries higher rates of engraftment failure and disease relapse.
Umbilical cord blood transplantation (UCBT) represents an alternative donor source, whose inherent immune properties offer the potential to reduce GVHD while preserving the GVL effect. However, the limited cell dose in single cord blood units results in delayed hematopoietic reconstitution, high infection rates, and elevated early mortality, restricting its broader application in adult patients.
Against this background, transplantation strategies combining the advantages of different donor sources have become a major research focus. The 'haplo-cord hematopoietic stem cell transplantation' strategy, which combines haploidentical peripheral blood stem cells with unrelated umbilical cord blood stem cells, has been proposed. This approach integrates the rapid hematopoietic engraftment of haploidentical stem cells with the immunomodulatory properties of cord blood, thereby accelerating hematopoietic recovery and reducing the risk of acute and chronic GVHD. Furthermore, the incorporation of immunomodulatory agents such as low-dose anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCY) has led to simultaneous control of both transplantation-related mortality and relapse.
Domestic investigators reported that patients with relapsed/refractory acute leukemia (r/r-AL) who received combined haplo-HSCT and UCB-assisted transplantation exhibited superior leukemia-free survival and lower relapse rates compared with haploidentical transplantation alone, with 2-year overall survival, progression-free survival, cumulative incidence of relapse, and non-relapse mortality of 35.5%, 35.5%, 25.9%, and 38.0%, respectively. An international study comparing double UCBT (dUCBT) with haplo-cord transplantation for hematologic malignancies demonstrated that haplo-cord transplantation was associated with faster neutrophil and platelet engraftment, lower risks of grade II-IV acute GVHD and chronic GVHD, reduced relapse risk, and superior GVHD- and relapse-free survival compared with dUCBT.
In recent years, with the increasing incidence of AML and MDS, post-transplant relapse has become the primary obstacle to long-term therapeutic success. International multicenter data indicate that disease relapse remains the leading cause of transplant failure (59% for matched sibling donors vs. 51% for unrelated donors), followed by severe GVHD and infection. Although conventional strategies including re-induction chemotherapy, second transplantation, and donor lymphocyte infusion (DLI) have been explored, their efficacy is limited by high relapse rates, severe toxicities, and modest survival benefits, failing to meet current clinical needs.
Therefore, the development of novel transplantation models that enhance GVL while controlling GVHD has become an urgent bottleneck to address. Combined donor transplantation strategies represent one promising approach toward this goal. To date, several countries have conducted exploratory studies of the haplo-cord regimen, reporting faster hematopoietic recovery, lower rejection risk, and reduced relapse rates. Multiple centers in China have also initiated clinical validation with encouraging results.
The applicant's research team has developed and implemented a haplo-cord HSCT protocol based on low-dose ATG plus PTCY, with proven safety and efficacy in clinical practice. Compared with conventional haploidentical or single cord blood transplantation, this regimen achieved significantly higher relapse-free survival in patients with relapsed/refractory disease, effectively reduced the incidence of chronic GVHD, and improved quality of life and survival expectancy, with 2-year overall survival, disease-free survival, and GVHD- and relapse-free survival of 64.9%, 64.5%, and 60.8%, respectively. Notably, nearly half of the patients achieved dominant cord blood engraftment, challenging the traditional view that cord blood serves only an auxiliary role.
In the present prospective multicenter cohort study, we aim to further investigate the long-term efficacy of this combined transplantation strategy in patients with AML and high-risk MDS. By comparing immune reconstitution, relapse rates, GVHD, and other prognostic outcomes between cord blood-dominant and haploidentical-dominant engraftment, we intend to define its optimal indications and establish high-level evidence to optimize hematopoietic stem cell transplantation regimens.
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice.
Specific research objectives: 1. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates. 2. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis. 3. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: haplo-cord HSCT · Drug: Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
Patients with disease status in CR and MRD-negative before transplantation received the FA3Cy2Bu3 regimen: Fludarabine 25 mg/m² for 3 days, Cytarabine 2 mg/m² for 3 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. All other patients received the FA5Cy2Bu3 regimen: Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. Following the conditioning regimen, patients underwent haploidentical-cord blood hematopoietic stem cell transplantation. Haploidentical hematopoietic stem cells were infused on day 0, and umbilical cord blood hematopoietic stem cells were infused on day 6.
Drug pages: FludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BusulfanStudies of BusulfanBusulfan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Antilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MelphalanStudies of MelphalanMelphalan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients with disease status in CR and MRD-negative before transplantation received the FA3Cy2Bu3 regimen: Fludarabine 25 mg/m² for 3 days, Cytarabine 2 mg/m² for 3 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. All other patients received the FA5Cy2Bu3 regimen: Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. Following the conditioning regimen, patients underwent haploidentical-cord blood hematopoietic stem cell transplantation. Haploidentical hematopoietic stem cells were infused on day 0, and umbilical cord blood hematopoietic stem cells were infused on day 6.
Overall Survival (OS)
Time frame: 3 years after transplantation
Progression-Free Survival(PFS)
Time frame: 3 years after transplantation
Disease-Free Survival(DFS)
Time frame: 3 years after transplantation
GVHD and Relapse-Free Survival(GRFS)
Time frame: 3 years after transplantation
Non-Relapse Mortality(NRM)
Time frame: 3 years after transplantation
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Beginning 3 months and ending 3 years after the publication of results
Access criteria: Access to de-identified IPD and supporting documents will be available to all researchers upon application to the principal investigator. Approval will be granted following review, and data will be provided via direct contact with the study team.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.
Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 36 months is below that.
Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Cytarabine · Busulfan · Antilymphocyte Serum · Melphalan · Cyclophosphamide
Fujian Medical University Union Hospital →